Nicholas A Vitanza, Michelle Choe, Christopher Brown, Adam Beebe, Ada Kong, Lisa Rogers, Susan Jacob, Elena Mano, Kimberly Abuan, Stephanie Mgebroff, Catherine Lindgren, Joshua A Gustafson, Ashley L Wilson, Alyssa Noll, Rebecca Ronsley, Erin E Crotty, Sarah E S Leary, Jessica B Foster, Navin Pinto, Juliane Gust, Rebecca A Gardner, Julie R Park, Michael C Jensen
{"title":"用于治疗儿童中枢神经系统肿瘤的局部 CAR T 细胞:研究药物服务药房活动。","authors":"Nicholas A Vitanza, Michelle Choe, Christopher Brown, Adam Beebe, Ada Kong, Lisa Rogers, Susan Jacob, Elena Mano, Kimberly Abuan, Stephanie Mgebroff, Catherine Lindgren, Joshua A Gustafson, Ashley L Wilson, Alyssa Noll, Rebecca Ronsley, Erin E Crotty, Sarah E S Leary, Jessica B Foster, Navin Pinto, Juliane Gust, Rebecca A Gardner, Julie R Park, Michael C Jensen","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A major obstacle in translating the therapeutic potential of chimeric antigen receptor (CAR) T cells to children with central nervous system (CNS) tumors is the blood-brain barrier. To overcome this limitation, preclinical and clinical studies have supported the use of repeated, locoregional intracranial CAR T-cell delivery. However, there is limited literature available describing the process for the involvement of an investigational drug service (IDS) pharmacy, particularly in the setting of a children's hospital with outpatient dosing for CNS tumors.</p><p><strong>Objectives: </strong>To describe Seattle Children's Hospital's experience in clinically producing CAR T cells and the implementation of IDS pharmacy practices used to deliver more than 300 intracranial CAR T-cell doses to children, as well as to share how we refined the processing techniques from CAR T-cell generation to the thawing of fractionated doses for intracranial delivery.</p><p><strong>Methods: </strong>Autologous CD4+ and CD8+ T cells were collected and transduced to express HER2, EGFR, or B7-H3-specific CAR T cells. Cryopreserved CAR T cells were thawed by the IDS pharmacy before intracranial delivery to patients with recurrent/refractory CNS tumors or with diffuse intrinsic pontine glioma/diffuse midline glioma.</p><p><strong>Results: </strong>The use of a thaw-and-dilute procedure for cryopreserved individual CAR T-cell doses provides reliable viability and is more efficient than typical thaw-and-wash protocols. Cell viability with the thaw-and-dilute protocol was approximately 75% and was always within 10% of the viability assessed at cryopreservation. Cell viability was preserved through 6 hours after thawing, which exceeded the 1-hour time frame from thawing to infusion.</p><p><strong>Conclusion: </strong>As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery.</p>","PeriodicalId":73775,"journal":{"name":"Journal of hematology oncology pharmacy","volume":"14 4","pages":"148-154"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375759/pdf/","citationCount":"0","resultStr":"{\"title\":\"Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.\",\"authors\":\"Nicholas A Vitanza, Michelle Choe, Christopher Brown, Adam Beebe, Ada Kong, Lisa Rogers, Susan Jacob, Elena Mano, Kimberly Abuan, Stephanie Mgebroff, Catherine Lindgren, Joshua A Gustafson, Ashley L Wilson, Alyssa Noll, Rebecca Ronsley, Erin E Crotty, Sarah E S Leary, Jessica B Foster, Navin Pinto, Juliane Gust, Rebecca A Gardner, Julie R Park, Michael C Jensen\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A major obstacle in translating the therapeutic potential of chimeric antigen receptor (CAR) T cells to children with central nervous system (CNS) tumors is the blood-brain barrier. To overcome this limitation, preclinical and clinical studies have supported the use of repeated, locoregional intracranial CAR T-cell delivery. However, there is limited literature available describing the process for the involvement of an investigational drug service (IDS) pharmacy, particularly in the setting of a children's hospital with outpatient dosing for CNS tumors.</p><p><strong>Objectives: </strong>To describe Seattle Children's Hospital's experience in clinically producing CAR T cells and the implementation of IDS pharmacy practices used to deliver more than 300 intracranial CAR T-cell doses to children, as well as to share how we refined the processing techniques from CAR T-cell generation to the thawing of fractionated doses for intracranial delivery.</p><p><strong>Methods: </strong>Autologous CD4+ and CD8+ T cells were collected and transduced to express HER2, EGFR, or B7-H3-specific CAR T cells. Cryopreserved CAR T cells were thawed by the IDS pharmacy before intracranial delivery to patients with recurrent/refractory CNS tumors or with diffuse intrinsic pontine glioma/diffuse midline glioma.</p><p><strong>Results: </strong>The use of a thaw-and-dilute procedure for cryopreserved individual CAR T-cell doses provides reliable viability and is more efficient than typical thaw-and-wash protocols. Cell viability with the thaw-and-dilute protocol was approximately 75% and was always within 10% of the viability assessed at cryopreservation. Cell viability was preserved through 6 hours after thawing, which exceeded the 1-hour time frame from thawing to infusion.</p><p><strong>Conclusion: </strong>As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery.</p>\",\"PeriodicalId\":73775,\"journal\":{\"name\":\"Journal of hematology oncology pharmacy\",\"volume\":\"14 4\",\"pages\":\"148-154\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375759/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of hematology oncology pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hematology oncology pharmacy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:将嵌合抗原受体(CAR)T细胞的治疗潜力应用于中枢神经系统(CNS)肿瘤患儿的一个主要障碍是血脑屏障。为了克服这一限制,临床前和临床研究支持使用重复、局部颅内递送 CAR T 细胞的方法。然而,描述研究用药服务(IDS)药房参与过程的文献有限,尤其是在儿童医院门诊给药治疗中枢神经系统肿瘤的情况下:目的:介绍西雅图儿童医院临床生产 CAR T 细胞的经验,以及为儿童提供 300 多份颅内 CAR T 细胞的 IDS 药房实践,并分享我们如何改进从 CAR T 细胞生成到解冻颅内给药分馏剂量的处理技术:方法:收集自体 CD4+ 和 CD8+ T 细胞并转导表达 HER2、表皮生长因子受体或 B7-H3 特异性 CAR T 细胞。在向复发性/难治性中枢神经系统肿瘤或弥漫性桥脑胶质瘤/弥漫性中线胶质瘤患者进行颅内注射前,由IDS药房对冷冻保存的CAR T细胞进行解冻:对低温保存的单个 CAR T 细胞剂量采用解冻稀释程序可提供可靠的存活率,而且比典型的解冻水洗方案更有效。采用解冻-稀释方案的细胞存活率约为 75%,与低温保存时评估的存活率相比,始终保持在 10%以内。细胞存活率在解冻后 6 小时内得以保持,超过了从解冻到输注的 1 小时时限:随着采用性免疫疗法领域的发展,它将继续为致命性中枢神经系统恶性肿瘤患者带来希望。
Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.
Background: A major obstacle in translating the therapeutic potential of chimeric antigen receptor (CAR) T cells to children with central nervous system (CNS) tumors is the blood-brain barrier. To overcome this limitation, preclinical and clinical studies have supported the use of repeated, locoregional intracranial CAR T-cell delivery. However, there is limited literature available describing the process for the involvement of an investigational drug service (IDS) pharmacy, particularly in the setting of a children's hospital with outpatient dosing for CNS tumors.
Objectives: To describe Seattle Children's Hospital's experience in clinically producing CAR T cells and the implementation of IDS pharmacy practices used to deliver more than 300 intracranial CAR T-cell doses to children, as well as to share how we refined the processing techniques from CAR T-cell generation to the thawing of fractionated doses for intracranial delivery.
Methods: Autologous CD4+ and CD8+ T cells were collected and transduced to express HER2, EGFR, or B7-H3-specific CAR T cells. Cryopreserved CAR T cells were thawed by the IDS pharmacy before intracranial delivery to patients with recurrent/refractory CNS tumors or with diffuse intrinsic pontine glioma/diffuse midline glioma.
Results: The use of a thaw-and-dilute procedure for cryopreserved individual CAR T-cell doses provides reliable viability and is more efficient than typical thaw-and-wash protocols. Cell viability with the thaw-and-dilute protocol was approximately 75% and was always within 10% of the viability assessed at cryopreservation. Cell viability was preserved through 6 hours after thawing, which exceeded the 1-hour time frame from thawing to infusion.
Conclusion: As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery.